Instem Stock

Instem Equity

Delisted·Nov 20, 2023

The The Equity of Instem (INS.L) as of Aug 10, 2026 is 53.36 M GBP. In the previous year, The Equity was 47.30 M GBP — a change of 12.81% (higher).

Equity

53.36 MGBP

YoY

12.81%

Last updated:

In 2026, Instem's equity was 53.36 M GBP, a 12.81% increase from the 47.30 M GBP equity in the previous year.

Access this data via the Eulerpool API

Instem Stock analysis

What does Instem do? Instem PLC is a company specialized in providing software solutions for the health and life sciences. It is headquartered in Abingdon, Oxfordshire and operates internationally. The company was founded in 2000 and has been listed on the London Stock Exchange since 2004. Instem's business model is based on helping life science companies optimize and automate their workflows. They offer a wide range of software products tailored to the specific needs of their customers. This includes systems for documenting animal experiments, clinical data collection, and solutions for regulatory drug submissions. One of Instem's key divisions is the Preclinical Solutions Division, which helps life science companies effectively plan and conduct their preclinical studies. The products in this division support the creation of study protocols, planning experimental procedures, and documenting study results. Additionally, customers of the Preclinical Solutions Division can access assistance with data collection and analysis, as well as comprehensive consulting services. Another important division of Instem is the Clinical Solutions Division, which supports clinical research facilities in conducting clinical trials. Their solutions include clinical data collection, study monitoring, and data submission to regulatory authorities. The Clinical Solutions Division also provides support for quality control and the production of statistical reports. Instem is also active in other areas, such as in vitro diagnostics and chemical approval. In these fields, the company offers a range of software solutions that aid in data collection, analysis, and reporting. A key factor that sets Instem apart from its competitors is its close collaboration with the life science community. The company works closely with customers, regulatory agencies, and interest groups to ensure that its products meet industry requirements and standards. In addition, the company has established close relationships with leading clinical and research institutions worldwide. In summary, Instem PLC is a significant provider of software solutions for the health and life sciences. The company has experienced impressive growth in recent years and strengthened its position in key market segments. Instem is well positioned to continue benefiting from the increasing demand for software solutions in the health and life sciences industry. Instem is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Instem's Equity

Instem's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Instem's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Instem's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Instem's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Instem’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Instem stock

The Equity of Instem is 53.36 M GBP in 2026.

The Equity of Instem changed from 47.30 M GBP to 53.36 M GBP, representing a 12.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Instem since 2006 – with annual values, charts, and detailed analysis.

The Equity's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Instem historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Instem

All Key Metrics — Instem